ReviewOncologyPosttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations
Section snippets
Endometrial cancer
Endometrial cancer is the most common gynecologic cancer and the fourth most common cancer in women. Yearly, there are approximately 44,000 new endometrial cancer diagnoses and 8000 deaths in the United States.1 Commonly, patients experience symptoms such as abnormal or postmenopausal bleeding, which warrant further investigation with ultrasound scanning and/or endometrial sampling. The combination of symptoms and diagnostic testing results in 83% of patients being diagnosed in the early stages
Ovarian cancer
Ovarian cancer affects almost 22,000 women each year in the United States and results in >13,000 deaths yearly.1 Although responsible for <30% of all gynecologic malignancies, ovarian cancer accounts for >50% of deaths. These results stem from a lack of accurate screening tools and symptoms that are vague and often not specific, which result in approximately 75% of patients being diagnosed with advanced disease.6 Since the 1970s, the median overall survival of patients with advanced ovarian
Cervical cancer
More than 12,000 women are diagnosed with cervical cancer each year in the United States.1 Patients are diagnosed with stage I disease in 50% of cases, and the 5-year survival rate for this group exceeds 90%.6 However, recurrence rates for this group of patients are high, ranging from 10–20%.68 The treatment of recurrent cervical cancer depends greatly on the primary therapy that is used and the location of recurrence. Patients with locally recurrent disease can be offered salvage treatments
Vulvar cancer
With 3900 new cases and 920 deaths annually in the United States, vulvar cancer is uncommon and represents approximately 4% of malignancies of the female genital tract and 0.6% of all cancers in women.1 Radical local excision of the vulva and inguinofemoral lymphadenectomy has been the standard surgical therapy for nearly 8 decades. More recent advances have included the introduction of preoperative chemoradiation for large primary tumors that involve the urethra, vagina, or anus and the
Vaginal cancer
Primary cancer of the vagina is an uncommon malignancy. With approximately 2300 cases diagnosed annually in the United States, vaginal cancer comprises approximately 3% of all malignant neoplasms of the female genital tract.1 Given the rarity of the disease, there is a paucity of information to guide posttreatment surveillance for patients with vaginal cancer. There are no data to support the routine use of follow-up vaginal cytologic evaluation or imaging in the asymptomatic patient.
Comment
Although gynecologic cancers account for only 10% of all new cancer cases in women, the number of survivors from these malignancies approaches 20%.1, 86 Improvements in cancer care have resulted in almost 10 million cancer survivors, and this number is expected to grow at an even faster rate than ever before.86 Thus, the determination of the most clinically and cost-effective surveillance for the detection of recurrence is critical.
As survivorship increases, transitioning patients from oncology
Acknowledgment
The Society of Gynecologic Oncologists' (SGO) Clinical Practice Committee has developed a series of Clinical Documents that are designed in part to improve the overall quality of women's cancer care, to reduce the use of unnecessary, ineffective, or harmful interventions, and to facilitate the treatment of patients with a goal to maximum the chance of benefit with a minimum risk of harm and at an acceptable cost.
SGO Clinical Documents remain strictly confidential and are not to be disclosed or
References (91)
Follow-up of the asymptomatic patient with ovarian cancer
Gynecol Oncol
(1994)- et al.
A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study
Gynecol Oncol
(2004) - et al.
Survival after relapse in patients with endometrial cancer: results from a randomized trial
Gynecol Oncol
(2003) - et al.
Pattern of failure and value of follow-up procedures in endometrial and cervical cancer patients
Gynecol Oncol
(2007) - et al.
Surveillance for recurrent endometrial carcinoma: development of a follow-up scheme
Gynecol Oncol
(1995) - et al.
Follow-up after primary therapy for endometrial cancer: a systematic review
Gynecol Oncol
(2006) - et al.
Cost-effectiveness of routine vaginal cytology for endometrial cancer surveillance
Gynecol Oncol
(2006) - et al.
Postsurgical surveillance of patients with FIGO stage I/II endometrial adenocarcinoma
Gynecol Oncol
(1995) - et al.
An evaluation of routine follow-up of patients treatment for endometrial carcinoma
Gynecol Oncol
(1994) - et al.
Efficacy of routine follow-up in patients with recurrent uterine cancer
Gynecol Oncol
(2007)
Value and cost evaluation of routine follow-up for patients with clinical stage I/II endometrial cancer
Eur J Cancer
Computed tomography in endometrial carcinoma
Obstet Gynecol
Treatment of pulmonary recurrences in patients with endometrial cancer
Gynecol Oncol
Part I: chemotherapy for epithelial ovarian cancer: treatment at first diagnosis
Lancet Oncol
Post-therapy surveillance and after-care in ovarian cancer
Eur J Obstet Gynecol Reprod Biol
Surveillance of patients after initial treatment of ovarian cancer
Crit Rev Oncol Hematol
The follow-up of ovarian cancer
Semin Oncol
Implications of second-look laparotomy in the context of optimally resected stage II ovarian cancer: a non-randomized comparison using an explanatory analysis: a Gynecologic Oncology Group study
Gynecol Oncol
risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels
Ann Oncol
Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study
Ann Oncol
Surveillance for recurrent ovarian cancer: survival impact or lead-time bias?
Gynecol Oncol
CA125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma: a systematic review of meta-analysis
Eur J Rad
The impact of PET-CT in suspected recurrent ovarian cancer: a prospective multi-centre study as part of the Australian PET Data Collection Project
Gynecol Oncol
Fertility and recurrence results of conservative surgery for borderline ovarian tumors
Gynecol Oncol
Ultrasound, physical examination, and CA125 measurement for the detection of recurrence after conservative surgery for early borderline ovarian tumors
Gynecol Oncol
Ovarian cancer incidence in the United States, 1992–1999
Gynecol Oncol
Ovarian stromal and germ cell tumors
Semin Oncol
Granulosa cell tumor of the ovary
Cancer Treat Rev
Recurrent cervical carcinoma after radical hysterectomy
Gynecol Oncol
Posttherapy surveillance of women with cervical cancer: an outcomes analysis
Gynecol Oncol
Value of routine follow-up procedures for patients with stage I/II cervical cancer treated with combined surgery-radiation therapy
Ann Oncol
The role of PET scanning in the detection of recurrent cervical cancer
Gynecol Oncol
Surveillance FDG-PET detection of asymptomatic recurrences in patients with cervical cancer
Gynecol Oncol
Could follow-up different modalities play a role in asymptomatic cervical cancer relapses diagnosis?An Italian multicenter retrospective analysis
Gynecol Oncol
A prospective study of the accuracy of 18Fluorodeoxyglucose positron emission tomography (18FDG PET) in identifying sites of metastasis prior to pelvic exenteration
Gynecol Oncol
26th Annual report on the results of treatment in gynecological cancer: carcinoma of the vulva
Int J Gynaecol Obstet
Long-term survival and disease recurrence in patients with primary squamous cell carcinoma of the vulva
Gynecol Oncol
Cancer statistics, 2010
CA Can J Clin
Views of primary care providers on follow up care of cancer patients
Fam Med
Comparison of patient and physician expectations for cancer survivorship care
J Clin Oncol
Adult cancer survivorship: evolution, research, and planning care
CA Cancer J Clin
SEER cancer statistics review
Randomized phase III trial of whole abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group study
J Clin Oncol
Endometrial carcinoma
Costs and benefits of routine follow-up after curative treatment for endometrial cancer
Can Med Assoc
Cited by (321)
Ovarian, Uterine, and Vulvovaginal Cancers: Screening, Treatment Overview, and Prognosis
2023, Medical Clinics of North AmericaRecurrent cervical cancer after trachelectomy diagnosed by hysteroscopy: A case report
2023, Gynecologic Oncology ReportsGerm cell, stromal, and other ovarian tumors
2023, DiSaia and Creasman Clinical Gynecologic Oncology
Authorship and contribution to the article is limited to the 7 authors indicated. There was no outside funding or technical assistance with the production of this article.